Wednesday, November 25, 2015 11:18:31 AM
If the FDA approval mentioned was outright FDA approval of the drug itself and not just clinical trials, then we could speculate on such a reaction to the stock PPS. But to say RGBP is going to run to 15 from .15 on FDA approval of clinical trials is pure fantasy land and no one else with any credibility should be supporting such a claim. Many small cap companies with products in later stages of development trade under $2.
If RGBP runs to even $1 on FDA approval of HemaX clinical trials I'll be happy and then if it runs to $2 on Orphan Status approval which is to follow, that would be very good. If that is accompanied by other significant developments, it might push higher, but let's not get caught up in $15 value with over 100 million shares issued.
Please. AIMO
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM